Sign in Subscribe
Cancer research

Investigator-Initiated Study of Telaglenastat and Nivolumab in Oncology Discussed by Researchers

Strategic Insights

— 1 min read

Researchers have made new findings in the field of oncology, specifically in the treatment of non-small cell lung cancer, by investigating the combination of telaglenastat and nivolumab. Telaglenastat, a glutaminase 1 inhibitor, targets the dysregulation in glutamine metabolism in cancer cells and the tumor microenvironment. A phase I/II trial was conducted to investigate the safety and efficacy of telaglenastat combined with nivolumab in patients with advanced solid tumors. The study included a total of 118 patients across different cohorts, with the most frequently reported adverse events being fatigue, nausea, and photophobia.

Key Takeaways:

  • The combination of telaglenastat and nivolumab did not show a pattern of efficacy across different study cohorts.
  • The overall response rate (ORR) was 8.4% (n = 9) in the response-assessable analysis set, which includes 107 patients in dose expansion and recommended phase II dose of dose escalation.
  • The ORR was 24% in 25 patients with clear-cell renal cell carcinoma (ccRCC) who were checkpoint inhibitor-naive, 5.9% in 17 patients with ccRCC after nivolumab, and 0% in 9 patients with ccRCC after other prior anti-PD-1/PD-L1.
  • Telaglenastat in combination with nivolumab was generally well-tolerated, with the most frequently reported adverse events being fatigue, nausea, and photophobia.
  • The study included a total of 118 patients across different cohorts, with a 3 + 3 design for dose escalation and Simon's two-stage design for expansion in phase II.

Statistics:

  • There were 118 patients across different cohorts in the phase I/II study.
  • The overall response rate (ORR) was 8.4% (n = 9) in the response-assessable analysis set.
  • The ORR was 24% (n = 6) in 25 patients with clear-cell renal cell carcinoma (ccRCC) who were checkpoint inhibitor-naive.
  • The ORR was 5.9% (n = 1) in 17 patients with ccRCC after nivolumab.

Sources:

  • A Phase I/ii Study of the Safety and Efficacy of Telaglenastat (Cb-839) In Combination With Nivolumab In Patients With Metastatic Melanoma, Renal Cell Carcinoma, and Non-small-cell Lung Cancer. ESMO Open, 2025;10(5).
  • NewsRx. Investigators at University of Texas MD Anderson Cancer Center Report Findings in Non-Small Cell Lung Cancer [A Phase I/ii Study of the Safety and Efficacy of Telaglenastat (Cb-839) In Combination With Nivolumab In Patients With Metastatic ...]. Immunotherapy Weekly. June 18, 2025; p 2003.

Read more